CN111315374A - 合成的赖氨酸类似物和模拟物的用于抗病毒用途的方法和组合物 - Google Patents

合成的赖氨酸类似物和模拟物的用于抗病毒用途的方法和组合物 Download PDF

Info

Publication number
CN111315374A
CN111315374A CN201880070088.0A CN201880070088A CN111315374A CN 111315374 A CN111315374 A CN 111315374A CN 201880070088 A CN201880070088 A CN 201880070088A CN 111315374 A CN111315374 A CN 111315374A
Authority
CN
China
Prior art keywords
mimetic
arginine
tranexamic acid
virus
synthetic lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880070088.0A
Other languages
English (en)
Chinese (zh)
Inventor
F.默多克
R.默多克
W.P.斯图尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antiviral Technology Co Ltd
Original Assignee
Antiviral Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antiviral Technology Co Ltd filed Critical Antiviral Technology Co Ltd
Publication of CN111315374A publication Critical patent/CN111315374A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880070088.0A 2017-08-27 2018-08-09 合成的赖氨酸类似物和模拟物的用于抗病毒用途的方法和组合物 Pending CN111315374A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762550656P 2017-08-27 2017-08-27
US62/550656 2017-08-27
US201862664555P 2018-04-30 2018-04-30
US62/664555 2018-04-30
PCT/US2018/046023 WO2019045989A1 (en) 2017-08-27 2018-08-09 METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS

Publications (1)

Publication Number Publication Date
CN111315374A true CN111315374A (zh) 2020-06-19

Family

ID=65525881

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880070088.0A Pending CN111315374A (zh) 2017-08-27 2018-08-09 合成的赖氨酸类似物和模拟物的用于抗病毒用途的方法和组合物

Country Status (11)

Country Link
US (3) US11413279B2 (https=)
EP (2) EP3672584A4 (https=)
JP (3) JP2020531586A (https=)
KR (1) KR102706114B1 (https=)
CN (1) CN111315374A (https=)
AU (2) AU2018324427B2 (https=)
BR (1) BR112020003735A2 (https=)
CA (1) CA3073685A1 (https=)
MX (2) MX2020002156A (https=)
WO (1) WO2019045989A1 (https=)
ZA (1) ZA202001472B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023505641A (ja) * 2019-10-29 2023-02-10 トラネキサミック テクノロジーズ， エルエルシー 有効性の増強のための合成リジンアナログ、誘導体、模倣物又はプロドラッグと医薬剤との相乗的組合せ
EP4103167A4 (en) * 2020-02-14 2024-03-13 Tranexamic Technologies, LLC METHODS AND COMPOSITIONS FOR THE ANTIMICROBIAL USE OF SYNTHETIC LYSINE ANALOGS, DERIVATIVES, MIMETICS AND PRODRUGS
JP7830159B2 (ja) * 2021-02-26 2026-03-16 ライオン株式会社 コロナウイルスの細胞侵入抑制剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010189301A (ja) * 2009-02-17 2010-09-02 Toshihito Eto 新型インフルエンザ感染症に対する医薬組成物およびその利用
CN103405384A (zh) * 2013-09-01 2013-11-27 吴静 氨甲环酸的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203827A1 (en) * 1994-10-28 1996-05-09 Gerard Voerman Novel family of protease inhibitors, and other biologic active substances
WO2000037071A1 (en) * 1998-12-21 2000-06-29 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
ES2156731B1 (es) 1999-05-31 2002-02-16 Grifols Grupo Sa Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
US7056947B2 (en) 2002-07-05 2006-06-06 Georgia Tech Research Corp. Aza-peptide epoxides
WO2004032915A1 (ja) * 2002-10-11 2004-04-22 Daiichi Pharmaceutical Co., Ltd. 抗インフルエンザウイルス剤
JP2008115168A (ja) * 2006-10-12 2008-05-22 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤
CA2742817A1 (en) * 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
US20120082677A1 (en) * 2010-10-01 2012-04-05 Sherif Salah Abdul Aziz Compositions for the treatment of hcv and hbv
US20140271923A1 (en) * 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010189301A (ja) * 2009-02-17 2010-09-02 Toshihito Eto 新型インフルエンザ感染症に対する医薬組成物およびその利用
CN103405384A (zh) * 2013-09-01 2013-11-27 吴静 氨甲环酸的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
V. LOZITSKY等: "Anti-influenza Efficacy of Combination Apply of Proteolytic", 《PROGRAM AND ABSTRACTS / ANTIVIRAL RESEARCH》 *

Also Published As

Publication number Publication date
US11413279B2 (en) 2022-08-16
EP3672584A1 (en) 2020-07-01
MX2020002156A (es) 2020-07-20
JP2025166032A (ja) 2025-11-05
EP4681713A2 (en) 2026-01-21
US20200323837A1 (en) 2020-10-15
KR102706114B1 (ko) 2024-09-11
JP2023123440A (ja) 2023-09-05
KR20200052310A (ko) 2020-05-14
AU2024203839A1 (en) 2024-06-27
MX2023009499A (es) 2023-08-23
AU2018324427B2 (en) 2024-03-07
ZA202001472B (en) 2022-05-25
BR112020003735A2 (pt) 2020-09-01
EP3672584A4 (en) 2021-05-05
US20260007649A1 (en) 2026-01-08
JP2020531586A (ja) 2020-11-05
AU2018324427A1 (en) 2020-04-09
WO2019045989A1 (en) 2019-03-07
CA3073685A1 (en) 2019-03-07
US20220288050A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
AU2024203839A1 (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
SA96160590B1 (ar) تركيبة صيدلانية
US20150374759A1 (en) Method for Treatment of Sores and Lesions of the Skin
AU740944B2 (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
JPS59130223A (ja) 相乗作用を示す抗ヘルペス組成物
PL217628B1 (pl) Zastosowanie resweratrolu do wytwarzania leku wywierającego działanie inhibitorowe na replikację wirusa grypy do zapobiegania i/lub leczenia infekcji wywołanej wirusem grypy
ITRM20060163A1 (it) Composizione spray ad uso topico per il tratamento e la prevenzione delle infezioni labiali da herpes simplex
DK2374461T3 (en) Piroxicam for the prophylactic and therapeutic treatment of herpes infections
HK40026056A (en) Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics
CN1213757C (zh) Dna病毒感染的协同治疗
US20230201309A1 (en) Compositions for the treatment of a respiratory condition
US12171732B2 (en) Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections
US20110070321A1 (en) Method and Composition for Cutaneous Treatment of Herpes Simplex Infections
US12357651B2 (en) Systems and methods for use of adenosine triphosphate (ATP) to relieve symptoms of COVID-19 and related infections
US20220249416A1 (en) Synergistic combinations of synthetic lysine analogs, derivatives, mimetics, or prodrugs and pharmaceutical agents for enhanced efficacy
MXPA99010447A (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
EP3006020A1 (en) Method for treating recurring skin and mucous membrane diseases caused by hsv-1 and hsv-2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40026056

Country of ref document: HK